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Keywords: solid tumor; children; transplantation; CD34 + cells For the treatment of childhood solid tumors, we performed a pilot feasibility study of consecutive high-dose therapies, in which each course was followed by transDespite the fact that childhood solid tumors are generally plantation with granulocyte colony-stimulating factorchemosensitive and that multimodality therapy has signifimobilized peripheral blood cells which had been separcantly improved the outcome, subgroups continue to do ated into CD34-positive and -negative fractions by an poorly. Poor prognostic features include metastasis and a
Isolex system (Baxter). Positive selection of CD34
؉ cells bulky primary tumor. Long-term survival is extremely rare has been associated with inevitable cell loss. To overfor patients who have primary refractory or relapsed discome this loss, CD34
؉ cells that had migrated into the ease. These problems may be solved through the use of negative fraction were saved and used for the first transhigh-dose chemotherapy, especially in patients with chemoplant, which was followed by a second transplant after sensitive tumors, since the effectiveness of anticancer thera 3-to 5-month interval. In this phase I feasibility study, apy depends on both the dose intensity of chemotherapy the results in six children were evaluated for safety and and the timing of drug administration. 1 Dose intensity can engraftment. Multi-drug cytoreductive regimens using be improved either by increasing the dosage of the drug ranimustine (MCNU), melphalan, thiotepa, carboplatin, given at the same intervals, by reducing the delay between cyclophosphamide or VP-16 were comparable between each cycle, or by using stem cell transplantation support. the two transplant procedures in terms of their intenAt present, the efficacy of autologous bone marrow transsity. 
CD34(
؊ ) fraction. The number of days required to achicells has been widely used. However, major drawbacks of eve an ANC Ͼ0.5 ؋ 10 9 /l and a platelet count this strategy include a variable period of cytopenia due to Ͼ20 ؋ 10 9 /l and Ͼ50 ؋ 10 9 /l were, respectively, 14.5, inevitable cell loss and a high cost.
and 19.5 in the first transplant with CD34
؊ cells, To improve the outcome in children with solid tumors and 13.5, 18.0 and 25.0 in the second transplant with associated with poor prognostic factors with intensifying CD34 ؉ cells, with no essential difference between the chemotherapy, we initiated a strategy of administering multwo treatments. Although the small number of patients, tiple 'mini-transplants' given in rapid succession, each with the variation in clinical status and treatment, and the the support of peripheral blood stem cells (PBSC). short follow-up invalidate any evaluation of the theraIn particular, we evaluated a new consecutive-autograft peutic benefit of this strategy, the encouraging results concept, in which cells that had been recovered in the support the feasibility of this strategy, which enables an CD34-negative fraction are used in the initial transplant.
escalation of dose intensity with an improved
The basic idea for this study was that the intensity of treatcost/benefit ratio. The remaining patients were mobilized by G-CSF alone (10 to the development of strategies for clinical application of g/kg/day for 5 days). Details of the procedure for colenriched CD34
+ cells. lecting blood cells have been described elsewhere. [4] [5] [6] [7] Briefly, a Fenwal CS-3000 Plus cell separator (Baxter Limited, Deerfield, IL, USA) was operated using a smallMaterials and methods volume collection chamber (SVCC) and a granulocyte chamber to process 100-350 ml of blood per kg body weight. Cells were recovered in 50-ml suspension.
Patients
Cells were then isolated with the Isolex 50 system (Baxter Limited) according to the manufacturer's instrucSix patients (one of each with ovarian tumor, testicular tumor, retinoblastoma, rhabdomyosarcoma, brain tumor tions. Briefly, cells were incubated with 0.5% human ␥-globulin (Polyglobin N; Bayer Japan, Tokyo, Japan) conand Wilms' tumor) were enrolled into this study with the written consent of the patients or their parents. This study taining PBS for 15 min to block intact Fc-receptors on the cell surface. After incubation, cells were washed with PBS was approved by the Institutional Review Board. There were four males and two females, and the patients ranged containing 1% HSA and incubated with anti-CD34 monoclonal antibody (9C5; Baxter) at a cell/antibody ratio of in age from 1 to 16 years (median, 9.5 years). All of the patients received surgery, and their characteristics and a 10 6 /0.5 g. After 30 min of incubation at 4°C with gentle rotation (4/min), cells were washed three times with PBS detailed history of previous therapy are summarized in Table 1 . Associated poor-prognosis factors included muland resuspended in IMDM with 1% HSA at 1-2 × 10 7 /ml. The anti-CD34 antibody-coated cells were incubated with tiple metastases (n = 3), recurrent tumor (n = 3) and wide local invasion (n = 1). All of these patients were considered sheep anti-mouse IgG1-coated microspheres (Dynabeads; Dynal Corporation, Oslo, Norway) for 30 min with rotation, to be eligible for this experimental consecutive high-dose therapy protocol.
and cells which were bound to the beads were then col- lected with a magnet using an Isolex system. Finally, Dynawere used in the initial transplant. This was followed by two to three courses of regular-dose chemotherapy for bead-bound cells were incubated with 200 U/ml of chymopapain (Chymocell-R; Baxter) for 15 min at 37°C. After further in vivo purging without rescue, before the final transplant with purified CD34 + cells. The detailed transincubation, CD34
+ cells were isolated from the beads using a magnet. The purity of the CD34 + cell fraction was 79%, plantation procedure has been reported elsewhere. 6-8 Dose intensities of cytoreductive regimens incorporating ranimuwith a recovery rate of 21%. Cells were mixed slowly with an equal volume of a freezing solution containing 8% stine (MCNU), melphalan, thiotepa, carboplatin, cyclophosphamide or VP-16 were considered to be comparable in human albumin, 12% HES, and 10% DMSO to give final concentrations of 6% HES and 5% DMSO. 8 Both CD34-each course of high-dose therapy, as summarized in Table  1 . No patient received total body irradiation. Thirty-six positive and -negative cells were transferred to 5-ml polypropylene tubes and then placed directly in an electric hours after completion of the cytoreductive regimen, the cells were rapidly thawed at 37°C and promptly infused freezer that maintained a temperature of Ϫ135°C (Sanyo Electric Co, Tokyo, Japan). The cells were stored in the into patients through a central venous catheter without additional post-thaw washing. Platelet transfusion was same freezer until use.
given as indicated to maintain the platelet count Ͼ20 × 10 9 /l. According to the treatment plan, all patients Hematopoietic progenitor assay were scheduled for at least two cycles of disease-oriented conventional-dose chemotherapy prior to the second transDetails of the progenitor assay have been published elsewhere. 9 Briefly, cells (0.5-2.0 × 10 5 /ml) were incubated in plant. All patients who had resectable residual disease with either normal or only minimally elevated tumor markers methylcellulose culture supplemented with 20% fetal bovine serum, 450 g/ml human transferrin, 20 ng/ml interleuafter high-dose therapy were selected to undergo additional surgery. kin-3, 20 ng/ml stem cell factor, 20 ng/ml G-CSF and 2 units/ml erythropoietin. Quadruplicate cultures were incubated for 14 days under humid conditions with 5% O 2 , 5% CO 2 and 90% N 2 , and scored for colony-forming unit Results granulocyte/macrophage (CFU-GM).
Procedure-related complications and engraftment Flow cytometric analysis of cells
All six patients completed the consecutive-PBSCT, with an interval ranging from 3 to 5 months. Procedure-related Aliquots (0.3-0.5 ml) of cell suspension (3 × 10 6 cells/ml) were mixed with 1.5 ml RPMI-1640 supplemented with complications were transient and clinically negligible. Engraftment data are summarized in Table 2 CD34( − ) fraction. After the first transplant, one patient was given scheduled using caliBRITE beads, and compensated using the CD33/CD34 fluorescent information from non-coexpressconventional dose consolidation chemotherapy before achieving a platelet count of 50 × 10 9 /l, and was removed ing controls stained with Becton Dickinson reagents. After function was verified, the samples were drawn into the flow from the comparative analysis of platelet engraftment speed for the first part of the transplant. In our historical data of cytometer using FSC and SSC as gating parameters and each group of 2 × 10 4 cells was analyzed. The flow cytofive conventional transplants for solid tumor with unmanipulated PBSC, the number of days required to achieve a metric data were analyzed using a gated analysis via a set of SSC-FL2 parameters for the CD34 + cells to calculate the ANC Ͼ0.5 × 10 9 /l and a platelet count Ͼ20 × 10 9 /l and Ͼ50 × 10 9 /l were, respectively, 12.0 (8-15), 20.0 (10-36), percentage of positive cells. Cell populations gated with a FL1-FL2 parameter were used in the analysis of lymphoand 37.0 (10-46). These numbers were, respectively, 14.5, 15.0, and 19.5 in the first transplants with the CD34-negacyte subsets. If the CD34 + population detected in 2 × 10 4 cells fell short of 1 × 10 3 cells, the count was extended to tive fraction, and 13.5, 18.0 and 25.0 in the second transplants with the CD34-positive fraction (Table 2) . Although a maximum of 5 × 10 4 cells to collect a sufficient number of CD34 + cells for evaluation. transplantation with the CD34-negative fraction tended to be associated with delayed recovery, there was no statistically significant difference in the recovery speed between Transplant procedure the two types of transplantation.
Although an evaluation of the therapeutic outcome is not In a previous study, we demonstrated that cells that had been recovered in the CD34-negative fraction still conthe major purpose of this study, which has only a short follow-up period, four of the six patients achieved complete tained a large number of CFU-GM. 10 Hence, these cells 150 remission, as evidenced by complete disappearance of isolation of CD34 + cells, this has been associated with inevitable cell loss. To minimize the risks and hazards of measurable tumor, and are currently surviving despite their initial poor risk. Two patients (cases 2 and 5) did not therapy and to improve the therapeutic ratio of stem cell therapy, we developed a consecutive-autograft concept, in respond to therapy.
which we recovered cells in the CD34-negative blood cell fraction and used them in the initial transplant. After positive selection, some CD34 bright cells may still migrate into Discussion the CD34-negative fraction, as do CD34 dull progenitor cells. To confirm this, we showed that the CD34-negative fraction Dose intensification and the sequential use of agents to overcome drug resistance may benefit some children with still contains a large number of progenitor cells (CFU-GM) which can support the supply of mature blood cells for high-risk solid tumors. The size of the cancer cell mass might be reduced by repeated, closely timed courses of some time. Finally, to eliminate the possibility of infusing malignant cells, patients then received a second and final high-dose chemotherapy. Although PBSC transplantation has become an established option for the treatment of varitransplant with CD34 + cells, which were indirectly depleted of malignant cells. ous malignant disorders, the therapeutic efficacy of this procedure has not been conclusively determined in the treatIn addressing the utility of new therapeutic strategies, any comparative analysis must address the clinical endment of childhood solid tumors. 6, [11] [12] [13] [14] For the treatment of solid tumors, it is likely that multiple intermediate-dose points of prolongation of survival and improved ultimate cure rate, safety of the procedure and cost-effectiveness. therapy delivers a higher dose rate with an improved safety margin than does a single high-dose therapy. To address We demonstrated that toxicity was acceptable with regards to disease prognosis, and the cost-effectiveness of this cell this point, we have developed a PBSCT program for pediatric patients. 15 fractionation approach was self-evident. The speed of hematopoiesis was essentially the same between the two phases Factors which limit the application of a multiple transplantation strategy include patient tolerance and the fact of the transplants, with no difference from the histological data of PBSCT with unmanipulated cells. 6 The current that an adequate amount of stem cells to support multiple courses of transplant may not be available in some patients.
results confirm the efficacy of high-dose therapy as either the first or subsequent salvage treatment in children with A double harvesting procedure has the obvious disadvantage of delayed engraftment, primarily due to disturbance solid tumors who do not become disease-free after conventional-dose chemotherapy, but who do respond to the of the stem cell pool and the marrow microenvironment by the preceding transplant procedure. It has been established reported protocol.
In conclusion, our procedure may make higher doses of that PBSC grafts are as durable as marrow grafts to fully support life-long hematopoiesis, and these are increasingly chemotherapy, as well as chemotherapy at more frequent intervals, more feasible, by ameliorating cytopenia, with an used for rescue after high-dose therapy. Most importantly, the graft size can be increased through the use of PBSC improved cost/benefit ratio and therapeutic margin. Reduction of the duration of aplasia may allow a wider rather than bone marrow, which makes a double-transplant procedure more feasible. The lower concentration of cancer application of multiple-cycle high-dose therapy, which may be of particular importance in certain malignant disorders. cells in PBSC graft than in marrow harvest products may be an additional advantage of the use of PBSC.
Recognizing that cancer cells are relatively enriched in the CD34-negative fraction, our next approach will include an Nevertheless, there is some evidence that contamination of grafts with tumor cells may contribute to recurrence additional purification of this fraction for negative depletion of cancer cells using disease-specific monoclonal antiupon reinfusion. 16 Although the effective depletion of cancer cells from a PBSC graft is possible through the positive bodies.
engraftment after peripheral blood stem cell autografts cryo-
